Compliance Doctors Medicine Pharma Companies 
pharmaphorum
JANUARY 8, 2021
The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. This is an increase in 14.2%
pharmaphorum
DECEMBER 15, 2021
Dialogue requires humility on the drug company’s side—accepting that sometimes we are wrong about matters we think we understand—and trust on the patients’ side that representatives of large, for-profit entities really have come to listen. The result may look similar to the role of ethics and compliance teams.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 30, 2022
The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine? The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas.
XTalks
MAY 3, 2024
While “it creates opportunities for organizations to truly look at [the patient] experience from a new lens,” she said, comms teams may find it challenging to change how they typically reach and respond to their audiences, especially as GLP-1 influencers increasingly overtake doctors as the most authoritative voices for interested patients.
XTalks
DECEMBER 20, 2023
Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.
pharmaphorum
NOVEMBER 19, 2020
By forming a thorough and insightful communications strategy based on patient needs, any advancements in efficacy can be matched by improved compliance and concordance. Healthcare companies that take this approach can improve their processes before commercialisation by breaking down internal silos. About the author.
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. Optimer binders are engineered to overcome these problems.
Expert insights. Personalized for you.
71 
Let's personalize your content